Cardiac Progenitor Cells: The Matrix Has You

CLOTILDE CASTALDOa ISOTTA CHIMENTib

aDepartment of Public Health, University of Naples “Federico II”, Naples, Italy; bDepartment of Medical Surgical Sciences and Biotechnologies, “La Sapienza” University of Rome, Latina, Italy

SUMMARY

Components of the cardiac extracellular matrix (ECM) are synthesized by residing cells and are continuously remodeled by them. Conversely, residing cells (including primitive cells) receive constant biochemical and mechanical signals from the ECM that modulate their biology. The pathological progression of heart failure affects all residing cells, inevitably causing profound changes in ECM composition and architecture that, in turn, impact on cell phenotypes. Any regenerative medicine approach must aim at sustaining microenvironment conditions that favor cardiogenic commitment of therapeutic cells and minimize pro-fibrotic signals, while conversely boosting the capacity of therapeutic cells to counteract adverse remodeling of the ECM. In this Perspective article, we discuss multiple issues about the features of an optimal scaffold for supporting cardiac tissue engineering strategies with cardiac progenitor cells, and, conversely, about the possible antifibrotic mechanisms induced by cell therapy. STEM CELLS TRANSLATIONAL MEDICINE 2018;00:000–000

SIGNIFICANCE

Cardiac tissue is made of multiple cell types and of intercellular substance called extracellular matrix (ECM). These two components influence each other at multiple levels, but this balance is significantly altered in pathological conditions, such as heart failure, where the physiological composition and features of all tissue components are deeply disrupted. Any proposal for novel therapies based on regenerative medicine must consider the restoration of a healthy crosstalk between cells and the ECM, at both biochemical and biomechanical level.

INTRODUCTION

The myocardium, as all mammalian tissues, consists of parenchymal and supporting cells enclosed in a highly complex milieu that is mostly formed by the extracellular matrix (ECM). Just as in a famous sci-fi movie “The Matrix” could affect perception and demeanor, so the ECM has a significant effect on cell behavior. Although it is recognized that the ECM plays a prominent role in cardiac development and in cardiac adaptation to physiological and pathological stimuli [1], the composition of the cardiac ECM has not been comprehensively defined yet. Admittedly, the ECM is an extremely intricate framework in dynamic equilibrium with cells, responding to cellular demand or injury with changes in its composition and architecture [2, 3]. Specifically, components of cardiac ECM are synthesized by residing cells, like fibroblasts, cardiac myocytes, and endothelial cells [4], and are continuously remodeled by the same cells according to ever-changing conditions. Nonetheless, residing cells (including primitive cells) receive constant biochemical and mechanical signals from the ECM that affect cell survival, proliferation, migration, and differentiation [5–7].

The pathological condition of ischemic heart disease affects the survival and activity of cardiac myocytes and other residing cells, inevitably causing profound changes in ECM composition and architecture that, in turn, impact upon cell behavior [8–10]. Cellular therapy has been introduced about two decades ago as a therapeutic strategy to replace the dead myocardium after ischemic injury, and has slowly led to the recognition that the hostile ischemic microenvironment tends to oppose any attempt of succeeding in regenerating the heart [11].

Indeed stem/progenitor cell therapy for heart failure is gradually advancing toward more effective approaches. So-called “first generation therapies,” based typically on unselected bone marrow cells, are gradually being surpassed by “second generation therapies” with cardiogenic cell types, such as resident cardiac progenitor cells (CPCs), and higher repair potency [12]. Multiple protocols and criteria have been proposed to isolate resident CPC populations intrinsically committed to cardiovascular lineages from the adult mammalian heart [13, 14]. Nonetheless, only few among them, with very strong transcriptomic similarity [15], have been successfully applied to human cardiac tissue from advanced heart failure patients, and subjected to phase I/II clinical trials [16].

A key concept for the above-mentioned progress is “combination therapy,” referring to either combining: (a) multiple...
synergic cell types, (b) cardiogenic cells with an appropriate support for tissue engineering, or (c) cell therapy with optimal tissue conditioning. These concepts highlight the importance of a multifactorial perspective on cardiac regenerative medicine (Fig. 1), where the crosstalk between the host microenvironment and regenerative cell type(s) determines indeed the therapeutic outcome [7, 17]. It is of great importance to create and sustain microenvironment conditions that favor cardiogenic commitment of therapeutic cells and minimize pro-fibrotic or inflammatory signals, while conversely boosting the capacity of therapeutic cells to promote tissue protection and counteract adverse remodeling of the ECM.

REGENERATING THE MYOCARDIUM BY THE “RIGHT” MATRIX

One possible approach to repair the tissue in all its components is to provide an exogenous matrix as an ideal substrate and support for cell transplantation. Several biomaterials, either natural or synthetic, have been used as ECM substitutes thus far [18–20]. Undoubtedly, collagen, gelatin, alginate, and fibrin are the most used among natural polymers, as they are naturally charged with numerous cell binding sites while ensuring high biocompatibility and biodegradability. Nonetheless, they lack critical mechanical properties, such as strength, stiffness, or elasticity. On the contrary, synthetic polymers, like polyglycolic acid, polyactic acid, and the relatively new polyglycerol sebacate, are tunable in their physical properties, but poor in biological activity, even though they can be loaded with biochemical signals in the form of ECM protein fragments [21, 22]. Several cell seeded scaffolds of natural and/or synthetic biomaterials have been evaluated in vivo and their outcomes have been recently reviewed [23], leading to the conclusion that, although groundbreaking advances were made through tissue engineering, the optimal cardiac scaffold capable of meeting the requirements critical to support functional improvement of the failing heart still represents a demanding challenge. Indeed, the spatial organization of structural ECM components at its nanoscale and microscale, and the biochemical complexity of the ECM cannot be fully recapitulated by synthetic scaffolds, due to the still nebulous knowledge about physical properties and exact composition of cardiac ECM, as well as to the limits of currently available technologies.

Since only the native ECM itself could deliver the ideal mechanical and biological properties to therapeutic cells, several studies have investigated the possibility of engineering the myocardium for regenerative medicine purposes by combining decellularized cardiac ECM with stem/progenitor cells [24–26], speculating that the intrinsically perfect combination of mechanical and biochemical properties of native cardiac ECM may control and ensure cell engraftment while driving stem/progenitor cell fate. Despite the synergistic effect of all ECM components, a direct supporting mechanism has been already reported for some ECM molecules like fibronectin, proven to be necessary for endogenous CPC proliferation and activation for repair through focal adhesion signaling [27]. The ECM’s influence on CPCs, though, may act at multiple levels: we have previously reported that human CPCs cultured short-term on cardiac fibroblast-derived ECM substrates from failing hearts release less trophic and anti-remodeling paracrine factors, such as tissue inhibitor of metalloproteinases 2 (TIMP2), compared to substrates from fibroblasts from healthy hearts [28]. Moreover, multiple studies have investigated several combinations of ECM

---

Figure 1. Representative scheme of a multiperspective approach to cardiac regeneration. Cardiogenic regenerative cells are selected not only for their differentiation potential, but also for their ability to affect endogenous remodeling and exert antifibrotic effects. Moreover, an optimized scaffold for cardiac tissue engineering should provide adequate mechanical stimulation and have the right composition to mimic the native ECM, in order to provide regenerative cells with the right cardiogenic microenvironment. Finally, the discovery of previously unknown mechanisms of action on cardiac regenerative cells of standard-of-care pharmacological treatments for heart failure, could introduce adjuvant strategies for cardiac cell therapy. Abbreviation: ECM, extracellular matrix
REGENERATION AGAINST FIBROSION

Even if locally providing optimal exogenous support to therapeutic stem/progenitor cells, the complex pathological process of cardiac remodeling and fibrosis in heart failure [10] may still hamper the overall efficacy of any regenerative strategy, due to detrimental cell-cell and cell-ECM crosstalk. Currently, there is still shortage of specific antifibrosis and anti-remodeling targeted therapies for heart failure. Although angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers, which are among the elective drugs for heart failure treatment, can indeed act directly on remodeling by reducing the detrimental effects of angiotensin II on cardiac fibroblasts activity [36], the discovery of novel targeted strategies would undoubtedly improve therapeutic efficacy. Multiple molecules are under clinical investigation, but many trials on antifibrotic drugs have been discouraging [37]. Interestingly, a majority of preclinical studies of cardiac cell therapy have evidenced how one of its main effects is the reduction of tissue fibrosis and remodeling, suggesting that a biological cell-based therapy may provide per se an effective antifibrotic strategy [38].

In fact, multiple studies have shown how transplanted therapeutic cells can oppose remodeling of the endogenous ECM, mediating a temporally and spatially regulated release of beneficial factors, and yielding reduced collagen deposition, increased collagen degradation, and matrix metalloproteases (MMPs) levels [39]. Direct benefits on ECM remodeling have been reported with resident CPCs, which exert multiple basic beneficial effects in animal models of cardiac cell therapy [40]. In fact, CPC exosomes can paracrinally prime fibroblasts toward a cardioprotective and pro-angiogenic phenotype, simultaneously reducing adverse remodeling [41, 42] and fibroblast proliferation [43]. The pathways responsible for these mechanisms are largely unknown, but it has been reported that CPCs release many paracrine factors, including modulators of ECM remodeling (e.g., TIMPs) [44] and endoglin, which can inhibit TGF-β1/Smad signaling in fibroblasts [45].

Therefore, cell therapy can significantly act as an antifibrotic treatment for the heart, simultaneously helping to unravel key pathways for specific antifibrotic outcomes.

Moreover, under the above-mentioned perspective of combined therapies, a biological regenerative approach could be synergistically merged with existing standard care treatments that act on multiple pathways (Fig. 1). As an example, it has been suggested that beta-blockers (BBs) could represent an adjuvant therapy for cardiac regenerative protocols. BBs are an elective medicine for heart failure [46], and act at multiple levels [47], also indirectly affecting cardiac fibroblasts activation [48]. It has been reported that BBs can enhance mesenchymal stem cell therapy for myocardial infarction by increasing cell survival [49]. Moreover, they have been shown to sustain CPC viability [50] and their cardiogenic phenotype in human resident CPCs, while reducing their pro-fibrotic features, such as collagen I, mir-21, and mir-29 expression levels [51]. Interestingly, BBs have been also associated to successful cardiac recovery, or “reverse remodeling,” during left ventricular assist device (LVAD) support, that is near-normalization of the multiple myocardial abnormalities in advanced heart failure patients after mechanical unloading through LVAD implantation [52]. In fact, patients receiving BBs experience more frequently cardiac recovery [53], suggesting an intriguing mechanistic connection between reversing cardiac tissue adverse remodeling, and promoting antifibrotic and cardiogenic features of resident regenerative cells [54].

CONCLUSION

Tissue regeneration involves replenishment of lost parenchymal and stromal cells, and also ECM restoration to physiological composition, architecture, and biomechanical features. Optimal outcomes ideally require a productive crosstalk between cells and the ECM to boost the regenerative potency of progenitor cells while simultaneously providing the right ECM scaffold and minimizing fibrosis. First generation therapies for heart failure were based on the utopian expectation that a single injection of noncardiac primitive cells would be enough for effective cardiac regeneration. Almost two decades of preclinical and clinical research are now suggesting that a complex result requires a complex strategy, such as integrating the many aspects necessary for completely rebuilding tissue structure and composition. “The Matrix is everywhere,” and every cell “develops a natural equilibrium with the surrounding environment” (freely edited from: Wachowski Lana and Andy, “The Matrix” motion picture, Warner Bros 1999), but the “right” cell on the “wrong” substrate may not behave as desired.

ACKNOWLEDGMENTS

This manuscript was partially supported by Grant 20123E8FH4 from MIUR to I.C. and C.C.

AUTHOR CONTRIBUTIONS

C.C. and I.C.: conception and design, manuscript writing, final approval of the manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicated no potential conflicts of interest.

DISCLAIMERS

Authors have nothing to disclose.
REFERENCES

1. Bowers SL, Banerjee I, Baudino TA. The extracellular matrix: At the center of it all. J Mol Cell Cardiol 2010;48:474–482.
2. Borg TK, Baudino TA. Dynamic interactions between the cellular components of the heart and the extracellular matrix. Pflugers Arch 2011;462:69–74.
3. Louzao-Martinez L, Vink A, Harakalova M et al. Characteristic adaptations of the extracellular matrix in dilated cardiomyopathy. Int J Cardiol 2016;220:634–646.
4. Gupta V, Grande-Allen KJ. Effects of static and cyclic loading in regulating extracellular matrix synthesis by cardiovascular cells. Cardiovasc Res 2006;72:375–383.
5. Rienks M, Papageorgiou AP, Frangogiannis NG et al. Myocardial extracellular matrix: An ever-changing and diverse entity. Circ Res 2014;114:872–888.
6. Pesce M, Messina E, Chimenti I et al. Cardiac mechanosensation: A life-long story from early beats to aging and failure. Stem Cells Dev 2017;26:1723–1731.
7. Mauretti A, Spaans S, Bax NAM et al. Cardiac progenitor cells and the interplay with their microenvironment. Stem Cells Int 2017;2017:1741582.
8. Frangogiannis NG. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest 2017;127:1600–1612.
9. Castaldo C, Di Meglio F, Nurzynska D et al. CD117-positive cells in adult human heart are localized in the subepicardium, and their activation is associated with laminin-1 and alpha6 integrin expression. Stem Cells 2008;26:1723–1731.
10. Schirone L, Palmerio S, Noella C et al. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev 2017;2017:4034003.
11. Sanchez PL, Fernandez-Santos ME, Costanza S et al. Acellular human heart matrix: A critical step toward whole heart grafts. Biomaterials 2015;61:279–289.
12. Oberwallner B, Brodarac A, Anic P et al. Human cardiac extracellular matrix supports myocardial lineage commitment of pluripotent stem cells. Eur J Cardiothorac Surg 2015;47:416–425.
13. Di Meglio F, Nurzynska D, Rovamo V et al. Optimization of human myocardium decellularization method for the construction of implantable patches. Tissue Eng Part C Methods 2017;23:525–539.
14. Konstandin MH, Toko H, Gueltem GM et al. Fibronecint is essential for reparative cardiac progenitor cell response after myocardial infarction. Circ Res 2013;113:115–125.
15. Pagano F, Angelini G, Castaldo C et al. Normal versus pathological cardiac fibroblast-derived extracellular matrix differentially modulates cardiocyte-derived cell paracrine properties and commitment. Stem Cells Int 2017;2017:7396462.
16. Mauretti A, Bax NA, van Marion MH et al. Cardiomyocyte progenitor cell mecha-noresponse unrevealed: Stress avoidance and mechanosense development. Integr Biol 2016;8:991–1001.
17. Williams C, Budina E, Stoppel WL et al. Cardiac extracellular matrix-fibrin hybrid scaffolds with tunable properties for cardiovascular tissue engineering. Acta Biomater 2015;14:84–95.
18. Tallawi M, Rai R, Bocaccini AR et al. Effect of substrate mechanics on cardiomyo-cyte maturation and growth. Tissue Eng Part B Rev 2015;21:157–165.
19. van Marion MH, Bax NA, van Turnhout MC et al. Behavior of CMPCs in unidirectional constrained and stress-free 3D hydrogels. J Mol Cell Cardiol 2015;87:79–91.
20. Kc P, Shah M, Liao J et al. Prevascularization of decellularized porcine myocardial matrix. J Mater Sci Mater Med 2012;23:1835–1847.
21. Rieder E, Steinacher-Nigisch A, Weigel G. Human immune-cell response towards diverse xenogeneic and allogeneic decellularized biomaterials. Int J Surg 2016;36:347–351.
22. Shyu KG. The role of endoglin in myocardial fibrosis. Acta Cardiol Sin 2017;33:461–467.
23. Fang L, Murphy AJ, Dart AM. A clinical perspective of anti-fibrotic therapies for cardio-vascular disease. Front Pharmacol 2017;8:186.
24. Elnakish MT, Kuppasamy P, Khan M. Stem cell transplantation as a therapy for cardiac fibrosis. J Pathol 2013;229:347–354.
25. Tseliou E, de Couto G, Terrovitis J et al. Angiogenesis, cardiomyocyte proliferation and anti-fibrotic effects underlie structural preservation post-infarction by intramyocardially-injected cardiospheres. PLoS One 2014;9:e88590.
26. Mallikas K, Zhang Y, Seinfeld J et al. Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. EMBO Mol Med 2013;5:191–209.
27. Gallet R, Dawkins J, Valle J et al. Exosomes secreted by cardiomyoblastic-derived cells reduce scarring, attenuate adverse remodeling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J 2017;38:201–211.
28. Tseliou E, Fouad J, Reich H et al. Fibroblasts rendered anti-fibrotic, anti-apoptotic, and angiogenic by priming with cardiomyoblast-derived extracellular membrane vesicles. J Am Coll Cardiol 2015;66:599–611.
29. Lang JK, Young RF, Ashraf H et al. Inhibiting extracellular vesicle release from human cardiomyocyte derived cells with lentiviral knockdown of nSMase2 differentially effects proliferation and apoptosis in cardiomyocytes, fibroblasts and endothelial cells in vitro. PLoS One 2016;11:e0165926.
30. Stassna M, Chimenti J, Marban E et al. Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics 2010;10:245–253.
31. Tseliou E, Reich H, de Couto G et al. Cardiomyocytes prevent adverse remodeling in chronic rat myocardial infarction: Roles of soluble endoglin and Tgf-beta signaling. Basic Res Cardiol 2014;109:443.
32. Chatterjee S, Blandi-Zoccai G, Abbate A et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: Network meta-analysis. BMJ 2013;346:f555.
33. Rehsia NS, Dhall NS. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol 2010;15:85–90.
34. Naumachi N, Sato VH, Moongkarnrd P et al. Sustained beta-AR stimulation induces synthesis and secretion of growth factors in cardiac myocytes that affect on cardiac fibroblast activation. Life Sci 2018;193:257–269.
35. Hassan F, Meduru S, Taguchi K et al. Carvedilol enhances mesenchymal stem cell therapy for myocardial infarction via inhibition of...
of caspase-3 expression. J Pharmacol Exp Ther 2012;343:62–71.
50 Khan M, Mohsin S, Avitabile D et al. β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res 2013;112:476–486.
51 Chimenti I, Pagano F, Cavarretta E et al. Beta-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells. Sci Rep 2016;6:36774.
52 Birks EJ. Molecular changes after left ventricular assist device support for heart failure. Circ Res 2013;113:777–791.
53 Wever-Pinzon O, Drakos SG, McKellar SH et al. Cardiac recovery during long-term left ventricular assist device support. J Am Coll Cardiol 2016;68:1540–1553.
54 Chimenti I, Pagano F, Sciarretta S et al. Cardiac recovery during long-term LVAD: Is there an interaction between beta-blockers and cardiac progenitor cells? J Am Coll Cardiol 2017;69:1880–1881.